New drug trial aims to calm Schizophrenia's worst episodes
NCT ID NCT01499563
Summary
This study tested whether a new drug called ITI-007 could reduce symptoms in people with schizophrenia who were experiencing a sudden worsening of their psychosis. 335 participants were randomly assigned to receive either one of two doses of ITI-007, a placebo (inactive pill), or an existing antipsychotic medication (risperidone) for 28 days. The main goal was to see if ITI-007 was better than a placebo at lowering overall schizophrenia symptom scores.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Site
Little Rock, Arkansas, United States
-
Clinical Site
Garden Grove, California, United States
-
Clinical Site
Atlanta, Georgia, United States
-
Clinical Site
Rockville, Maryland, United States
-
Clinical Site
St Louis, Missouri, United States
-
Clinical Site
Willingboro, New Jersey, United States
-
Clinical Site
Philadelphia, Pennsylvania, United States
-
Clinical Site
Austin, Texas, United States
Conditions
Explore the condition pages connected to this study.